1344 related articles for article (PubMed ID: 28410618)
1. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic biomarkers in the blood of patients with urological malignancies.
Ellinger J; Müller SC; Dietrich D
Expert Rev Mol Diagn; 2015 Apr; 15(4):505-16. PubMed ID: 25719388
[TBL] [Abstract][Full Text] [Related]
3. Emerging concepts in liquid biopsies.
Perakis S; Speicher MR
BMC Med; 2017 Apr; 15(1):75. PubMed ID: 28381299
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
[TBL] [Abstract][Full Text] [Related]
5. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
Junqueira-Neto S; Batista IA; Costa JL; Melo SA
Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
[TBL] [Abstract][Full Text] [Related]
6. Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!
Fontanilles M; Duran-Peña A; Idbaih A
Curr Neurol Neurosci Rep; 2018 Mar; 18(3):13. PubMed ID: 29520561
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.
Takai E; Yachida S
World J Gastroenterol; 2016 Oct; 22(38):8480-8488. PubMed ID: 27784960
[TBL] [Abstract][Full Text] [Related]
8. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
[TBL] [Abstract][Full Text] [Related]
9. Research progress on liquid biopsy in oncology and its clinical applications.
Wang C; Li YM; Fang XD
Yi Chuan; 2017 Mar; 39(3):220-231. PubMed ID: 28420618
[TBL] [Abstract][Full Text] [Related]
10. Circulating biomarkers to guide systemic therapy for urothelial carcinoma.
Abbosh PH; Rosenberg JE; Plimack ER
Urol Oncol; 2016 Nov; 34(11):502-509. PubMed ID: 27751785
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy in the clinical management of bladder cancer: current status and future developments.
Kouba E; Lopez-Beltran A; Montironi R; Massari F; Huang K; Santoni M; Chovanec M; Cheng M; Scarpelli M; Zhang J; Cimadamore A; Cheng L
Expert Rev Mol Diagn; 2020 Feb; 20(2):255-264. PubMed ID: 31608720
[No Abstract] [Full Text] [Related]
12. Advanced liquid biopsy technologies for circulating biomarker detection.
Soda N; Rehm BHA; Sonar P; Nguyen NT; Shiddiky MJA
J Mater Chem B; 2019 Nov; 7(43):6670-6704. PubMed ID: 31646316
[TBL] [Abstract][Full Text] [Related]
13. Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?
Zhang W; Xia W; Lv Z; Ni C; Xin Y; Yang L
Cell Physiol Biochem; 2017; 41(2):755-768. PubMed ID: 28214887
[TBL] [Abstract][Full Text] [Related]
14. Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies.
Zeuschner P; Linxweiler J; Junker K
Expert Rev Mol Diagn; 2020 Feb; 20(2):151-167. PubMed ID: 31499007
[No Abstract] [Full Text] [Related]
15. Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach.
Ricciardi E; Giordani E; Ziccheddu G; Falcone I; Giacomini P; Fanciulli M; Russillo M; Cerro M; Ciliberto G; Morrone A; Guerrisi A; Valenti F
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835424
[TBL] [Abstract][Full Text] [Related]
16. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies.
Ralla B; Stephan C; Meller S; Dietrich D; Kristiansen G; Jung K
Crit Rev Clin Lab Sci; 2014 Aug; 51(4):200-31. PubMed ID: 24878357
[TBL] [Abstract][Full Text] [Related]
17. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?
Miyamoto DT; Lee RJ
Urol Oncol; 2016 Nov; 34(11):490-501. PubMed ID: 27771279
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsies in lung cancer: the new ambrosia of researchers.
Rolfo C; Castiglia M; Hong D; Alessandro R; Mertens I; Baggerman G; Zwaenepoel K; Gil-Bazo I; Passiglia F; Carreca AP; Taverna S; Vento R; Santini D; Peeters M; Russo A; Pauwels P
Biochim Biophys Acta; 2014 Dec; 1846(2):539-46. PubMed ID: 25444714
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.
Lebofsky R; Decraene C; Bernard V; Kamal M; Blin A; Leroy Q; Rio Frio T; Pierron G; Callens C; Bieche I; Saliou A; Madic J; Rouleau E; Bidard FC; Lantz O; Stern MH; Le Tourneau C; Pierga JY
Mol Oncol; 2015 Apr; 9(4):783-90. PubMed ID: 25579085
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.
Batth IS; Mitra A; Manier S; Ghobrial IM; Menter D; Kopetz S; Li S
Ann Oncol; 2017 Mar; 28(3):468-477. PubMed ID: 27998963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
